The GLP-1 and GLP-1/GIP medications liraglutide, semaglutide and tirzepatide are licensed for weight loss in the UK but only around 220,000 people will be eligible for treatment with these on the NHS between 2025 and 2028
People monitoring effects often track IGF-1 and, if relevant, fasting glucose
Chirumbolo S, Valdenassi L, Tirelli U, Ricevuti G, Pandolfi S, Vaiano F, Galoforo A, Loprete F, Simonetti V, Chierchia M, Bellardi D, Richelmi T, Franzini M (2023b) The oxygen-ozone adjunct medical treatment according to the protocols from the Italian Scientific Society of Oxygen-Ozone Therapy: how ozone applications in the blood can influence clinical therapy success via the modulation of cell biology and immunity
Try to take it at the same time every morning to minimize side effects and variability